ArticleExperimental and therapeutic medicine2019
MicroRNA-382 inhibits cancer cell growth and metastasis in NSCLC via targeting LMO3.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- LncRNA SNHG6 role in clinicopathological parameters in cancers.European journal of medical research · 2023Review
- Circ_0007385 promotes the proliferation and inhibits the apoptosis of non-small cell lung cancer cells via miR-337-3p-dependent regulation of LMO3.Histology and histopathology · 2023Article
- Circ_0000052/miR-382-3p axis induces PD-L1 expression and regulates cell proliferation and immune evasion in head and neck squamous cell carcinoma.Journal of cellular and molecular medicine · 2023Article
- A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma.Genetics research · 2022Article
- MiR-223-3p attenuates the migration and invasion of NSCLC cells by regulating NLRP3.Frontiers in oncology · 2022Article
- miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC).Journal of gastrointestinal oncology · 2021Article
- circ_0005962 functions as an oncogene to aggravate NSCLC progression.Open medicine (Warsaw, Poland) · 2021Article
- Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer.International journal of clinical and experimental pathology · 2021Article
- LncRNA SNHG6 promotes LMO3 expression by sponging miR-543 in glioma.Molecular and cellular biochemistry · 2020Article
- Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.Frontiers in cell and developmental biology · 2019Review
- miR-744-5p Inhibits Non-Small Cell Lung Cancer Proliferation and Invasion by Directly Targeting PAX2.Technology in cancer research & treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have revealed a pivotal role of microRNAs (miRs) in regulating the initiation and development of multiple types of cancer. In the present study, it was discovered that miR-382 may be an important tumor suppressor in non-small cell lung cancer (NSCLC). It was demonstrated that miR-382 expression was downregulated in tumor tissues from patients with NSCLC compared with adjacent normal tissues. Furthermore, overexpression of miR-382 suppressed cell proliferation and cell migration of NSCLC cells. In addition, reverse transcription-quantitative polymerase chain reaction and the luciferase reporter assay revealed that LIM-only protein 3 (LMO3), an oncogene, acted as a direct target gene of miR-382. Notably, overexpression of miR-382 did not alter cell proliferation or migration in LMO3-silenced A549 cells. Furthermore, analysis of patient tissues indicated an elevation of LMO3 expression in tumor tissues compared with adjacent normal tissues and a negative association between miR-382 and LMO3 mRNA expression levels. Taken together, the present findings indicated that miR-382 inhibited NSCLC cell proliferation and metastasis by targeting LMO3, suggesting a tumor suppressor role of miR-382 in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.